|
Bravo-Perez C, Sola M, Teruel-Montoya R, Garcia-Malo MD, Ortuno FJ, Vicente V, de Arriba F, Jerez A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers (Basel). 2021 Aug 27;13(17):4332. doi: 10.3390/cancers13174332. PubMed PMID: 34503142; PubMed Central PMCID: PMC8430644.
AÑO: 2021; IF: 6.575
|
34503142
|
Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabanas V, Casanova M, Oriol A, Krsnik I, Perez-Montana A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood. 2021 Oct 28;138(17):1583-1589. doi: 10.1182/blood.2020009754. PubMed PMID: 34133718.
AÑO: 2021; IF: 25.476
|
|
Puig N, Hernandez MT, Rosinol L, Gonzalez E, de Arriba F, Oriol A, Gonzalez-Calle V, Escalante F, de la Rubia J, Gironella M, Rios R, Garcia-Sanchez R, Arguinano JM, Alegre A, Martin J, Gutierrez NC, Calasanz MJ, Martin ML, Couto MDC, Casanova M, Arnao M, Perez-Persona E, Garzon S, Gonzalez MS, Martin-Sanchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortes-Rodriguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Blade J, Niesvizky R, Mateos MV. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8. PubMed PMID: 34021118; PubMed Central PMCID: PMC8139975.
AÑO: 2021; IF: 9.812
|
|
Bravo-Perez C, Fernandez-Caballero M, Soler-Espejo E, Garcia-Torralba E, Sorigue M, Garcia-Malo MD, Jerez A, Vicente V, Roldan V, de Arriba F. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. J Thromb Thrombolysis. 2021 Oct;52(3):848-853. doi: 10.1007/s11239-021-02407-5. Epub 2021 Mar 1. PubMed PMID: 33649980.
AÑO: 2021; IF: 2.2
|
|
Puig N, Corchete-Sanchez LA, Perez-Moran JJ, Davila J, Paino T, de la Rubia J, Oriol A, Martin-Sanchez J, de Arriba F, Blade J, Blanchard MJ, Gonzalez-Calle V, Garcia-Sanz R, Paiva B, Lahuerta JJ, San-Miguel JF, Mateos MV, Ocio EM. Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers (Basel). 2020 Dec 3;12(12):3615. doi: 10.3390/cancers12123615. PubMed PMID: 33287189; PubMed Central PMCID: PMC7761692.
AÑO: 2020; IF: 6.639
|